Standout Papers

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical cou... 2021 2026 2022 2024175
  1. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial (2021)
    Christopher Butler, Jienchi Dorward et al. The Lancet

Immediate Impact

24 standout
Sub-graph 1 of 11

Citing Papers

The global prevalence of depression, anxiety, and sleep disorder among patients coping with Post COVID-19 syndrome (long COVID): a systematic review and meta-analysis
2024 Standout
Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions
2024 Standout
2 intermediate papers

Works of Emma Ogburn being referenced

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
2021 Standout
Trastuzumab-associated cardiac events in the Persephone trial
2016

Author Peers

Author Last Decade Papers Cites
Emma Ogburn 50 38 11 106 61 18 368
A. Herrero San Martín 34 13 1 146 79 18 391
Rodolfo Sbrojavacca 12 22 54 80 24 374
Adrian Root 18 30 4 36 83 13 360
Mohamad Sidani 77 12 4 32 77 23 313
Andrea Patton 10 12 59 76 19 386
Abdulmalik Alkatheri 13 12 1 34 36 22 308
Brooke Barlow 42 25 5 137 29 22 371
Fateme Monjazebi 28 30 1 113 59 18 412
Noah A. Schuster 45 63 5 25 49 14 374
Irma Convertino 23 14 1 179 35 29 376

All Works

Loading papers...

Rankless by CCL
2026